KIMBERLY PENLAND: Open Payments
NPI 1467443036 · FORT WAYNE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$480 in 32 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $336 · 2025 $480
Food & beverage: $480
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $140 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $35 |
| Novo Nordisk Inc | 2 | $34 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $34 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Corium, LLC | 1 | $17 |
| Exact Sciences Corporation | 1 | $15 |
Products named: CAPLYTA, VRAYLAR, UBRELVY, Kerendia, XIFAXAN, QULIPTA, LINZESS, REXULTI.
Industry payments across IN — which companies pay providers there.
